What are the differential diagnoses for a patient who is four months into anti‑tuberculosis therapy with isoniazid and rifampicin and is also taking apixaban and ivabradine, presenting with vomiting and fever?

Differential Diagnoses for Vomiting and Fever at 4 Months of Anti-TB Treatment

The most critical differential diagnosis in this patient is drug-induced hepatotoxicity from isoniazid and rifampicin, which requires immediate cessation of anti-TB medications and urgent liver function testing. 1, 2

Priority Differential Diagnoses

1. Drug-Induced Hepatotoxicity (Most Likely)

This is the primary concern at 4 months of treatment with isoniazid and rifampicin. Both drugs are hepatotoxic, and the combination significantly increases risk 3:

• Clinical presentation: Vomiting, fever, nausea, epigastric discomfort, and malaise are classic early symptoms
• Timeline: Hepatotoxicity typically manifests after weeks to months of therapy, with peak risk between 4-8 weeks but can occur at any point 4
• Critical action: Stop all anti-TB medications immediately and check liver enzymes (AST, ALT), bilirubin, and coagulation studies (PT/INR) 2
• Risk factors to assess: Alcohol use, pre-existing liver disease, concurrent hepatotoxic medications, nutritional status 5, 4

Common pitfall: Continuing anti-TB drugs despite symptoms can lead to fulminant hepatic failure and death 3. Do not wait for jaundice to appear—vomiting and fever alone warrant immediate evaluation.

2. Drug-Induced Fever (Isoniazid or Rifampicin)

Both medications can cause isolated drug fever without hepatotoxicity 6, 7:

• Presentation: High-grade fever (38-40°C), chills, nausea, vomiting occurring after each dose
• Key distinguishing feature: No rash, eosinophilia, or elevated liver enzymes initially
• Diagnosis: Fever resolves 24-48 hours after drug discontinuation; rechallenge reproduces symptoms 6

3. Paradoxical TB Reaction (Immune Reconstitution)

New or worsening symptoms despite appropriate treatment 2, 8, 9:

• Timing: Typically occurs 2-12 weeks after treatment initiation
• Presentation: Fever, new lymphadenopathy, worsening radiographic findings, or new organ involvement
• Critical distinction: Patient may show systemic improvement in some areas while developing new TB manifestations elsewhere 9
• Management: Continue anti-TB therapy; consider corticosteroids for severe cases 8

4. DRESS Syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)

Severe hypersensitivity reaction to anti-TB medications 10:

• Timing: Typically 2-8 weeks after drug initiation, but can occur later
• Key features: Fever, rash (maculopapular), facial edema, lymphadenopathy, eosinophilia (>1000/mm³), and internal organ involvement
• Check: Complete blood count with differential for eosinophilia, liver enzymes
• Management: Immediate drug discontinuation, systemic corticosteroids

5. Treatment Failure with Drug-Resistant TB

Consider if fever represents ongoing active TB 11:

• Risk factors: Previous TB treatment, exposure to known drug-resistant cases, origin from high-resistance areas
• Evaluation: Repeat sputum cultures and drug susceptibility testing
• Timeline consideration: At 4 months, cultures should be negative if treatment is effective

6. Vitamin K-Dependent Coagulation Disorder

Rifampicin can cause bleeding disorders 2:

• Presentation: May present with hematemesis (bloody vomiting), bleeding from other sites
• Check: PT/INR, coagulation studies
• Risk factors: Chronic liver disease, poor nutritional status, concurrent anticoagulants (notably, this patient is on apixaban)

7. Drug Interactions

Critical concern: Rifampicin is a potent enzyme inducer that significantly reduces apixaban levels, potentially causing therapeutic failure of anticoagulation 2. Conversely, loss of anticoagulation effect could lead to thromboembolic complications presenting with fever and vomiting.

• Ivabradine interaction: Rifampicin may reduce ivabradine efficacy, potentially causing cardiac decompensation

Immediate Diagnostic Algorithm

1. Stop all anti-TB medications immediately pending evaluation

2. Urgent laboratory testing:

   • Liver function tests (AST, ALT, alkaline phosphatase, bilirubin)
   • Complete blood count with differential (eosinophilia, thrombocytopenia)
   • Coagulation studies (PT/INR, PTT)
   • Renal function
   • Serum ferritin (if hemophagocytic syndrome suspected)

3. Clinical assessment:

   • Examine for rash, lymphadenopathy, hepatomegaly
   • Check for bleeding manifestations
   • Assess volume status and signs of hepatic encephalopathy

4. If liver enzymes elevated:

   • AST/ALT >3x upper limit of normal with symptoms = drug-induced hepatitis
   • Do not restart anti-TB drugs until normalized and expert consultation obtained 4

5. If liver enzymes normal:

   • Consider drug fever, paradoxical reaction, or DRESS
   • Evaluate for new TB manifestations (imaging, cultures)

Critical Management Points

• Never add a single drug back to a failing regimen 5
• Consult TB expert immediately for drug-resistant TB concerns or complex cases 5
• Report severe adverse events to FDA MedWatch and CDC Division of TB Elimination 5
• Coordinate with local health department for all suspected TB treatment complications 5

The combination of vomiting and fever at 4 months of isoniazid/rifampicin therapy is hepatotoxicity until proven otherwise—this is a medical emergency requiring immediate drug cessation and evaluation.